Genmab A/s

Genmab A/S has finalized its acquisition of Merus N.V., converting all remaining minority shares into cash and delisting the company.

Genmab A/S, through its subsidiary, increased its beneficial ownership in Merus N.V. to 72,828,509 common shares following a tender offer and subsequent acquisitions.

Genmab A/S, through its subsidiary, has increased its beneficial ownership in Merus N.V. to over 94% following a tender offer and subsequent share acquisitions.

Genmab A/S, through its subsidiary, acquired additional common shares of Merus N.V. at $97 per share following a tender offer, increasing its beneficial ownership to over 71.7 million shares.

Genmab A/S has successfully completed its tender offer and subsequent merger to acquire all outstanding shares of Merus N.V. for $97.00 per share, leading to its delisting from Nasdaq.

Genmab A/S has successfully acquired 94.8% of Merus N.V. common shares through a tender offer at $97.00 per share, moving towards full control and delisting.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have collectively increased their beneficial ownership in Genmab A/S to 5.3%, acquiring over 3.3 million shares.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly filed a Schedule 13G, reporting beneficial ownership of 5.5% of Genmab A/S common stock as of March 31, 2026.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd jointly reported a 6.6% beneficial ownership stake in Genmab A/S common stock.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5.8% beneficial ownership stake in Genmab A/S common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Genmab A/S as of March 31, 2025.